$ELDN: Eledon Pharmaceuticals, Inc. - Common Stock

Eledon Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for patients with rare diseases. The company's lead product candidate is ELND005, a novel, orally-available small molecule that is being developed for the treatment of Niemann-Pick disease type C (NPC). NPC is a rare, inherited disorder that affects the body's ability to break down cholesterol and other lipids. ELND005 has been shown to be effective in preclinical studies in models of NPC, and the company is currently conducting a Phase 1 clinical trial in patients with the disease.

In addition to ELND005, Eledon is also developing ELND003, a novel, orally-available small molecule that is being developed for the treatment of Friedreich's ataxia (FA). FA is a rare, inherited disorder that affects the nervous system. ELND003 has been shown to be effective in preclinical studies in models of FA, and the company is currently conducting a Phase 1 clinical trial in patients with the disease.

Eledon was founded in 2016 and is headquartered in Cambridge, Massachusetts. The company is led by CEO and President David Altshuler, who is a former senior executive at Biogen and Pfizer. Eledon is funded by a combination of venture capital and government grants.

The market for rare diseases is growing rapidly, as the number of known rare diseases continues to increase. The global rare disease market is expected to reach $265 billion by 2025. Eledon is well-positioned to capitalize on this growth, as it is developing two novel, potentially first-in-class therapies for rare diseases.

The company's lead product candidate, ELND005, has the potential to be a game-changer for patients with NPC. NPC is a devastating disease that currently has no effective treatment. ELND005 has the potential to provide patients with NPC with a much-needed treatment option.

Eledon's second product candidate, ELND003, also has the potential to be a major breakthrough. FA is a rare, but debilitating disease that affects the nervous system. ELND003 has the potential to slow the progression of FA and improve the quality of life for patients with the disease.

Eledon is a promising young company with a bright future. The company is developing two potentially groundbreaking therapies for rare diseases, and it is well-positioned to capitalize on the growing market for rare diseases. Investors should keep an eye on Eledon as it develops its pipeline of products.

Here are some additional details about ELND005 and ELND003:

• ELND005 is a small molecule that is designed to inhibit the activity of a protein called NPC1. NPC1 is essential for the breakdown of cholesterol and other lipids, and mutations in the NPC1 gene are responsible for NPC. ELND005 has been shown to be effective in preclinical studies in models of NPC, and the company is currently conducting a Phase 1 clinical trial in patients with the disease.
• ELND003 is a small molecule that is designed to activate a protein called frataxin. Frataxin is essential for the function of mitochondria, which are the cells' powerhouses. Mutations in the frataxin gene are responsible for FA. ELND003 has been shown to be effective in preclinical studies in models of FA, and the company is currently conducting a Phase 1 clinical trial in patients with the disease.

Eledon is a small company, but it has a big vision. The company is committed to developing innovative therapies for patients with rare diseases, and it has the potential to make a real difference in the lives of patients.